✅The prevalence of AMI (Acute Myocardial Infarction) approaches 3 million people worldwide, and the global prevalence of AMI is rising. It estimated that the current prevalence rate of 1,655 per 100,000 population. AMI causes irreversible damage to cardiomyocyte due to discontinuation of oxygen supply and may lead to impairment in diastolic and systolic function, even endanger our life.
✅For a long time, clinicians have been looking for serum diagnostic index of coronary heart disease with highly sensitive and specific. From AST to LDH, to CK, CK-MB, MB, and finally cardiac troponin (cTnI), high-sensitive cardiac troponin (hs-cTnI), the sensitivity and specificity of myocardial injury detection is increasing, hs-cTnI can detect very small myocardial injuries with high sensitivity and specificity. Generally speaking, the normal range of hs-cTnI is usually 0.00 to 0.50 ng/mL, greater than 0.2 ng/mL is the critical value, and greater than 0.5 ng/mL can diagnose acute myocardial infarction.
✅The hs-CtnI plays a leading role in AMI for its longer half-life and better stability. Traditional lab analysis, which takes much more time to deliver samples and thus may decrease the sensitivity in detection, Konsung fluorescence immunoassay analyzer can be a better optional for regular monitoring of hs-CtnI with the lab-quality precision and be more portable and flexible. It only requires 2 or 3 steps and takes 15 minutes to get test results. It uses disposable consumable and requires low maintenance, which means it can be adjustable for flexible usage scenarios, like clinics, health care center, pharmacies and so on.
✅Meanwhile, TSH, β-HCG，CTnl/CK-MB/MYO has already put it into market, furthermore , T3 and T4 will also put it into market soon. Konsung medical, care for your healthy life!
Post time: Mar-17-2023